clinical

De-risk your Glaucoma and AMD clinical trial with DARC

Effectively stratifies patient cohorts.

An increased DARC count is indicative of fast disease progression, so that you can readily identify enhanced cohorts that are most likely to demonstrate the efficacy of your drug.

Improves and accelerates
trial findings

DARC can be used as a surrogate endpoint, meaning you can efficiently identify the success of your trial rather than relying solely on current gold standards.

Saves time and money

By mitigating the risk of clinical failure and obtaining results within weeks rather than years, you can confidently reduce R&D costs and reduce lengthy trials.

Download our brochure